Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical and services company, has recieved the prestigious Investors in People Silver Award, recognising the high standard of people management, leadership and performance across the Group’s UK and US offices.
As part of the assessment, a staff questionnaire also showed the Group to be a 'Great Place to Work'.
Investors in People is the international standard for people management, defining what it takes to lead, support and manage people effectively to achieve sustainable results. Underpinning the Standard is the Investors in People framework, reflecting the latest workplace trends, essential skills and effective structures required to outperform in any industry. Investors in People enables organisations to benchmark against the best in the business on an international scale.
The accolade was given after a three day assessment which involved representatives of Investors in People visiting Clinigen’s UK sites and taking employee questionnaires to evaluate the Group’s people, processes, opportunities for development, and culture both in the UK and the US.
The assessment took place during the period of integration of Idis following its acquisition by Clinigen in April 2015, and marks the first formal recogition of the combined Group. The assessors highlighted that employees are optimistic about the Group and its growth plans. Employees are also united in their focus to keep patient care at the heart of everything they do.
The award marks Clinigen out as one of only 20 pharmaceutical companies in the UK to be accredited by Investors in People. In achieving Silver status, Clinigen is placed in the top ten percent of all companies recognised by Investors in People. In April 2015, Clinigen achieved the Investors in People Bronze status. The Group has continued to make significant improvements in just two years to now achieve the Silver accrediation.
Jessica Archer, Global HR Director of Clinigen, said:
"Receiving the Investors in People Silver accolade is a source of great pride for us. Not only does the award show our dedication to creating the best possible environment for staff, but also how we can provide the highest level of service to our clients."
Shaun Chilton, Chief Executive Officer of Clinigen, said:
"Since gaining the Bronze award in 2015, Clinigen has grown significantly to become the global leader in providing access to medicines. It is testament to the excellence of our people and culture of community to get this award so soon afterwards. We plan to use the output from this review as a building block for working towards a gold award in the coming years."
Paul Devoy, Head of Investors in People, said:
"We’d like to congratulate Clinigen for achieving the Investors in People Silver Award. This Standard shows Clinigen’s deep commitment to its staff, with the efforts made to raise its standards from Bronze two years ago being particularly commended. Investors in People is an internationally recognised accreditation, and Clinigen has proved it is an employer of the highest standards, not just in this country but around the world."
Clinigen Group plc
Shaun Chilton, Group Chief Executive Officer
Jessica Archer, Global HR Director
Tel: +44 (0) 1283 495010
Instinctif Partners (media)
Melanie Toyne-Sewell / Alex Shaw
Tel: +44 (0) 20 7457 2020
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.
The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.
For more information, please visit www.clinigengroup.com